Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SHE:002603)
16.16
-0.19 (-1.16%)
May 20, 2026, 11:25 AM CST
SHE:002603 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 7,897 | 7,815 | 6,506 | 10,315 | 12,520 | 10,111 |
Other Revenue | 15.74 | 15.74 | 6.99 | 3.48 | 13.04 | 6.12 |
| 7,912 | 7,831 | 6,513 | 10,318 | 12,533 | 10,117 | |
Revenue Growth (YoY) | 24.64% | 20.24% | -36.88% | -17.67% | 23.88% | 15.19% |
Cost of Revenue | 2,760 | 2,875 | 3,486 | 4,434 | 4,556 | 3,700 |
Gross Profit | 5,152 | 4,956 | 3,027 | 5,884 | 7,976 | 6,417 |
Selling, General & Admin | 2,584 | 2,499 | 2,935 | 3,297 | 3,871 | 3,931 |
Research & Development | 728.01 | 718.25 | 826.57 | 853.19 | 1,032 | 792.16 |
Other Operating Expenses | 141.66 | 123.65 | 91.72 | 99.27 | 203.45 | 138.41 |
Operating Expenses | 3,473 | 3,351 | 3,864 | 4,271 | 5,123 | 4,898 |
Operating Income | 1,679 | 1,605 | -837.02 | 1,613 | 2,853 | 1,519 |
Interest Expense | -1.29 | -1.06 | -29.01 | -38.9 | -33.8 | -33.97 |
Interest & Investment Income | 12.2 | 8.59 | 47.81 | 42.04 | 12.9 | 20.45 |
Currency Exchange Gain (Loss) | -1.93 | -1.93 | 1.46 | -0.21 | 4.16 | -1.25 |
Other Non Operating Income (Expenses) | -1.62 | -4.4 | -2.62 | -4.83 | -49.4 | -3.31 |
EBT Excluding Unusual Items | 1,686 | 1,606 | -819.39 | 1,611 | 2,787 | 1,501 |
Impairment of Goodwill | -6.24 | -6.24 | -6.24 | -0.52 | - | - |
Gain (Loss) on Sale of Investments | 5.27 | 3.92 | - | 39.35 | 11.5 | -21.9 |
Gain (Loss) on Sale of Assets | -1.04 | -0.89 | -0.49 | -0.82 | -3.11 | -3.37 |
Asset Writedown | -49.28 | -65.98 | -0.77 | -10.63 | -95.62 | -9.91 |
Other Unusual Items | 51.44 | 54.32 | 26.68 | 45.88 | 80.56 | 88.23 |
Pretax Income | 1,687 | 1,592 | -800.19 | 1,684 | 2,781 | 1,554 |
Income Tax Expense | 320.4 | 309.88 | -66.01 | 339.91 | 422.87 | 212.09 |
Earnings From Continuing Operations | 1,366 | 1,282 | -734.18 | 1,344 | 2,358 | 1,342 |
Minority Interest in Earnings | 3.19 | 4.75 | 9.67 | 8.08 | 4.98 | 2.22 |
Net Income | 1,369 | 1,286 | -724.52 | 1,352 | 2,363 | 1,344 |
Net Income to Common | 1,369 | 1,286 | -724.52 | 1,352 | 2,363 | 1,344 |
Net Income Growth | - | - | - | -42.76% | 75.82% | 10.27% |
Shares Outstanding (Basic) | 1,671 | 1,671 | 1,671 | 1,671 | 1,671 | 1,671 |
Shares Outstanding (Diluted) | 1,671 | 1,671 | 1,671 | 1,671 | 1,671 | 1,671 |
Shares Change (YoY) | 0.02% | 0.01% | -0.01% | -0.01% | 0.01% | -0.00% |
EPS (Basic) | 0.82 | 0.77 | -0.43 | 0.81 | 1.41 | 0.80 |
EPS (Diluted) | 0.82 | 0.77 | -0.43 | 0.81 | 1.41 | 0.80 |
EPS Growth | - | - | - | -42.76% | 75.81% | 10.27% |
Free Cash Flow | 1,786 | 1,531 | 320.62 | -155.38 | 3,274 | -144.87 |
Free Cash Flow Per Share | 1.07 | 0.92 | 0.19 | -0.09 | 1.96 | -0.09 |
Dividend Per Share | 0.800 | 0.800 | - | 0.300 | 0.500 | 0.300 |
Dividend Growth | - | - | - | -40.00% | 66.67% | -58.00% |
Gross Margin | 65.11% | 63.29% | 46.47% | 57.03% | 63.64% | 63.43% |
Operating Margin | 21.22% | 20.50% | -12.85% | 15.63% | 22.77% | 15.01% |
Profit Margin | 17.31% | 16.43% | -11.13% | 13.11% | 18.85% | 13.28% |
Free Cash Flow Margin | 22.57% | 19.55% | 4.92% | -1.51% | 26.12% | -1.43% |
EBITDA | 2,297 | 2,220 | -235.58 | 2,153 | 3,294 | 1,871 |
EBITDA Margin | 29.04% | 28.35% | -3.62% | 20.87% | 26.28% | 18.50% |
D&A For EBITDA | 618.32 | 614.94 | 601.44 | 540.64 | 440.6 | 352.61 |
EBIT | 1,679 | 1,605 | -837.02 | 1,613 | 2,853 | 1,519 |
EBIT Margin | 21.22% | 20.50% | -12.85% | 15.63% | 22.77% | 15.01% |
Effective Tax Rate | 19.00% | 19.47% | - | 20.18% | 15.21% | 13.65% |
Revenue as Reported | 7,912 | 7,831 | 6,513 | 10,318 | 12,533 | 10,117 |
Advertising Expenses | - | 114.07 | 169.83 | 257.93 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.